ImmuCell Corporation (NASDAQ:ICCC) Short Interest Up 44.1% in February

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 18,071 shares, a growth of 44.1% from the January 29th total of 12,544 shares. Based on an average daily trading volume, of 17,639 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.2% of the company’s stock are sold short. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 17,639 shares, the days-to-cover ratio is presently 1.0 days.

ImmuCell Stock Down 0.5%

NASDAQ ICCC traded down $0.03 during trading hours on Monday, reaching $6.54. 3,152 shares of the company traded hands, compared to its average volume of 13,103. The stock has a market capitalization of $59.19 million, a PE ratio of 25.15 and a beta of 0.26. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. ImmuCell has a 12 month low of $4.28 and a 12 month high of $7.60. The company has a 50 day moving average of $6.34 and a two-hundred day moving average of $6.09.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ICCC. Geode Capital Management LLC boosted its position in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the period. Mesirow Financial Investment Management Inc. grew its position in ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after buying an additional 24,303 shares in the last quarter. Finally, Steadtrust LLC increased its position in shares of ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 25,070 shares during the period. 13.47% of the stock is owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.